Cargando…

Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer

PURPOSE: To investigate the feasibility of dose escalation and hypofractionation of pelvic lymph node intensity modulated radiation therapy (PLN-IMRT) in prostate cancer (PCa). METHODS AND MATERIALS: In a phase 1/2 study, patients with advanced localized PCa were sequentially treated with 70 to 74 G...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reis Ferreira, Miguel, Khan, Atia, Thomas, Karen, Truelove, Lesley, McNair, Helen, Gao, Annie, Parker, Chris C., Huddart, Robert, Bidmead, Margaret, Eeles, Ros, Khoo, Vincent, van As, Nicholas J., Hansen, Vibeke N., Dearnaley, David P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science Inc 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697895/ https://www.ncbi.nlm.nih.gov/pubmed/28939224 http://dx.doi.org/10.1016/j.ijrobp.2017.07.041

Ejemplares similares

Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up
por: Creak, A, et al.
Publicado: (2013)

Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects
por: Dearnaley, D P, et al.
Publicado: (2005)

Dosimetry and Gastrointestinal Toxicity Relationships in a Phase II Trial of Pelvic Lymph Node Radiotherapy in Advanced Localised Prostate Cancer
por: Ferreira, M.R., et al.
Publicado: (2019)

IMRT clinical implementation: Prostate and pelvic node irradiation using Helios and a 120‐leaf multileaf collimator
por: Clark, C. H., et al.
Publicado: (2002)

Magnitude of observer error using cone beam CT for prostate interfraction motion estimation: effect of reducing scan length or increasing exposure
por: McNair, Helen A, et al.
Publicado: (2015)

The Intensity-Modulated Pelvic Node and Bladder Radiotherapy (IMPART) Trial: A Phase II Single-Centre Prospective Study
por: Tan, M.P., et al.
Publicado: (2020)

Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL)
por: Dearnaley, David, et al.
Publicado: (2019)

Role of Pelvic Lymph Node Dissection in Prostate Cancer Treatment
por: Joung, Jae Young, et al.
Publicado: (2011)

Pelvic lymph node dissection in high-risk prostate cancer
por: Haiquel, Luciano, et al.
Publicado: (2021)

Proton Therapy of Prostate and Pelvic Lymph Nodes for High Risk Prostate Cancer: Acute Toxicity
por: Choo, Richard, et al.
Publicado: (2021)

Construction of tissue microarrays from prostate needle biopsy specimens
por: Jhavar, S, et al.
Publicado: (2005)

Sense and Nonsense of an Extended Pelvic Lymph Node Dissection in Prostate Cancer
por: Van Baelen, Anthony, et al.
Publicado: (2012)

Inter-fraction movements of the prostate and pelvic lymph nodes during IGRT
por: Björeland, Ulrika, et al.
Publicado: (2018)

A narrative review of pelvic lymph node dissection in prostate cancer
por: Cheung, Douglas C., et al.
Publicado: (2020)

Impact of prostate focused alignment on planned pelvic lymph node dose
por: Kilian‐Meneghin, Joshua, et al.
Publicado: (2021)

Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment
por: Hafeez, Shaista, et al.
Publicado: (2017)

Impact of androgen-deprivation therapy on the outcome of dose-escalation prostate cancer radiotherapy without elective pelvic irradiation
por: Hou, Wei-Hsien, et al.
Publicado: (2017)

Postoperative elective pelvic nodal irradiation compared to prostate bed irradiation in locally advanced prostate cancer – a retrospective analysis of dose-escalated patients
por: Link, Carola, et al.
Publicado: (2019)

Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer
por: Parker, C C, et al.
Publicado: (2002)

Extended Salvage Pelvic Lymph Node Dissection in Patients with Recurrent Prostate Cancer
por: Osmonov, Daniar K., et al.
Publicado: (2014)

An IGRT margin concept for pelvic lymph nodes in high-risk prostate cancer
por: Groher, M., et al.
Publicado: (2017)

Feasibility of Dose Escalating [(18)F]fluciclovine Positron Emission Tomography Positive Pelvic Lymph Nodes During Moderately Hypofractionated Radiation Therapy for High-Risk Prostate Cancer
por: McDonald, Andrew M., et al.
Publicado: (2019)

Low rate of lymphedema after extended pelvic lymphadenectomy followed by pelvic irradiation of node-positive prostate cancer
por: Rasmusson, Elisabeth, et al.
Publicado: (2013)

Evaluation of nurse-led follow up for patients undergoing pelvic radiotherapy
por: Faithfull, S, et al.
Publicado: (2001)

MRI-guided pelvic lymph node biopsy via transrectal approach in prostate cancer
por: Hague, Christian, et al.
Publicado: (2020)

Comparison of prostate delineation on multimodality imaging for MR-guided radiotherapy
por: Pathmanathan, Angela U, et al.
Publicado: (2019)

Impact of daily soft‐tissue image guidance to prostate on pelvic lymph node (PLN) irradiation for prostate patients receiving SBRT
por: Tyagi, Neelam, et al.
Publicado: (2019)

Eliminating microscopic lymph node metastasis by performing pelvic lymph node dissection during radical prostatectomy for prostate cancer
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

Salvage Pelvic Lymph Node Dissection in Recurrent Prostate Cancer: Surgical and Early Oncological Outcome
por: Claeys, Tom, et al.
Publicado: (2015)

Clinical outcomes of definitive whole pelvic radiotherapy for clinical lymph node metastatic prostate cancer
por: Tsuchida, Keisuke, et al.
Publicado: (2020)

No germline mutations in the dimerization domain of MXI1 in prostate cancer clusters. The CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group.
por: Edwards, S. M., et al.
Publicado: (1997)

Prospective Evaluation of Probabilistic Dose-escalated IMRT in Prostate Cancer
por: Wegener, Daniel, et al.
Publicado: (2020)

Allelic imbalance in familial and sporadic prostate cancer at the putative human prostate cancer susceptibility locus, HPC1. CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group.
por: Dunsmuir, W. D., et al.
Publicado: (1998)

Pelvic lymph-node staging with (18)F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial -
por: Jansen, B. H. E., et al.
Publicado: (2020)

The feasibility and results of a population-based approach to evaluating prostate-specific antigen screening for prostate cancer in men with a raised familial risk
por: Melia, J, et al.
Publicado: (2006)

Recognising the challenges of implementing multi-centre adaptive plan of the day radiotherapy
por: Webster, Amanda, et al.
Publicado: (2022)

Radiation Therapy Dose Escalation to Clinically Involved Pelvic Sidewall Lymph Nodes in Locally Advanced Rectal Cancer
por: Hartvigson, Pehr E., et al.
Publicado: (2019)

Prostate specific antigen (PSA) persistence 6 weeks after radical prostatectomy and pelvic lymph node dissection as predictive factor of radiographic progression in node-positive prostate cancer patients
por: Kim, Jung Kwon, et al.
Publicado: (2019)

Is chronic prostatitis/chronic pelvic pain syndrome an infectious disease of the prostate?
por: Nickel, J. Curtis
Publicado: (2017)

The Clinical Genetics of Prostate Cancer
por: Kommu, Sashi, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_44orv8u7r83bneeq1gio9u37kv